Caxton Associates (New York)’s Quest Diagnostics DGX Stock Holding History

Caxton Associates (New York)’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$376K	Buy	+2,490	New	+$387K	0.01%	378
2023 Q4	–	Sell	-1,773	Closed	-$216K	–	479
2023 Q3	$216K	Buy	+1,773	New	+$236K	0.03%	350
2021 Q2	–	Sell	-5,065	Closed	-$650K	–	491
2021 Q1	$650K	Buy	+5,065	New	+$624K	0.06%	121
2019 Q1	–	Sell	-4,680	Closed	-$390K	–	397
2018 Q4	$390K	Buy	+4,680	New	+$439K	0.06%	142
2018 Q1	–	Sell	-9,973	Closed	-$982K	–	351
2017 Q4	$982K	Buy	9,973 +3,273	+49%	+$310K	0.05%	211
2017 Q3	$627K	Buy	6,700 +700	+12%	+$74.3K	0.02%	259
2017 Q2	$667K	Sell	6,000 -700	-10%	-$74K	0.03%	231
2017 Q1	$658K	Buy	+6,700	New	+$639K	﹤0.01%	191

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s DGX Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Quest Diagnostics (DGX) in Q4 2024: 2,490 shares worth $376K. The stake represents 0.01% of the portfolio and ranks #378 among its holdings. This is a return to the name: Caxton Associates (New York) previously reported a position in DGX as recently as Q3 2023.

Caxton Associates (New York) first reported a position in DGX in Q1 2017 and has held it in 8 quarters since. The position peaked at $982K in Q4 2017. 895 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

Caxton Associates (New York) held 2,490 shares of Quest Diagnostics worth $376K as of Q4 2024.
Quest Diagnostics was a new Caxton Associates (New York) position in Q4 2024.
Quest Diagnostics made up 0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #378 holding.
Caxton Associates (New York) first reported a position in Quest Diagnostics in Q1 2017 and has held it in 8 quarters since.
Caxton Associates (New York)'s Quest Diagnostics position peaked at $982K in Q4 2017.
895 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.